Su1802 EXTENDED INDUCTION RESPONSE OVER TIME IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB IN THE LUCENT-1 AND -2 TRIALS
Leggi →
Maggio 2024
Risultati per: Lesioni ulcerative dei genitali
Questo è quello che abbiamo trovato per te
Su1809 ASSESSMENT OF STEROID USE IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS WHO INITIATED A NEW JANUS KINASE INHIBITOR OR TUMOR NECROSIS FACTOR INHIBITOR USING DATA FROM A UNITED STATES CLAIMS DATABASE
Leggi →
Maggio 2024
Su1808 MIRIKIZUMAB IMPROVED BOWEL URGENCY, ABDOMINAL PAIN, AND FATIGUE IN PEDIATRIC PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 2 SHINE-1 STUDY
Leggi →
Maggio 2024
Su1807 MIRIKIZUMAB PHARMACOKINETICS AND EXPOSURE-RESPONSE IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 SHINE-1 STUDY
Leggi →
Maggio 2024
Su1805 EARLY MONITORING TREATMENT RESPONSE IN ULCERATIVE COLITIS: A MULTICENTER STUDY
Leggi →
Maggio 2024
Su1800 EFFICACY AND SAFETY OF MIRIKIZUMAB THERAPY IN PEDIATRIC PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 2 SHINE-1 STUDY
Leggi →
Maggio 2024
Su1797 ETRASIMOD SHOWS LOW RISK OF ADVERSE EVENTS FOLLOWING CONCOMITANT USE WITH OPIOIDS OR ANTIDEPRESSANTS IN PATIENTS WITH ULCERATIVE COLITIS
Leggi →
Maggio 2024
Su1796 POST-MARKETING SURVEILLANCE OF TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS IN JAPAN: A FINAL REPORT OF SAFETY AND EFFECTIVENESS DATA
Leggi →
Maggio 2024
Su1795 OZANIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR ULCERATIVE COLITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN JAPAN (J-TRUE NORTH)
Leggi →
Maggio 2024
Su1824 CLINICAL SIGNIFICANCE OF EOSINOPHILS IN CORTICOSTEROID THERAPY FOR ACTIVE ULCERATIVE COLITIS
Leggi →
Maggio 2024
Su1813 EXTERNALLY VALIDATED ARTIFICIAL INTELLIGENCE EXPLAINABLE INTERACTIVE TOOL FOR PREDICTING AND COMPARING THE DRUG SUSTAINABILITY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE ULCERATIVE COLITIS
Leggi →
Maggio 2024
Su1814 CLINICAL RELEVANCE OF BASELINE AND CHANGE IN URGENCY NUMERIC RATING SCALE SCORE FOR MIRIKIZUMAB TREATMENT FOR ULCERATIVE COLITIS
Leggi →
Maggio 2024
Su1818 EFFECT OF MIRIKIZUMAB ON CLINICAL AND ENDOSCOPIC OUTCOMES AFTER 1 ANTI-TNF FAILURE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Leggi →
Maggio 2024
Su1774 RELATIONSHIP BETWEEN SYMPTOM RESOLUTION AND CLINICAL RESPONSES AFTER 12 WEEKS OF TREATMENT WITH TULISOKIBART IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST HOC ANALYSIS FROM ARTEMIS-UC
Leggi →
Maggio 2024
Su1773 ACHIEVEMENT OF CLINICAL AND ENDOSCOPIC OUTCOMES BY BASELINE CORTICOSTEROID USE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO RECEIVED RISANKIZUMAB INDUCTION TREATMENT: A POST-HOC ANALYSIS OF THE INSPIRE STUDY
Leggi →
Maggio 2024
Su1771 SAFETY OF LONG-TERM OZANIMOD TREATMENT FOR UP TO 4 YEARS BY AGE GROUP IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION
Leggi →
Maggio 2024
